Medical Oncology

Andrew John Armstrong, MD

Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address andrew.armstrong@duke.edu

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996

Grants

Publications

Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Howard I. Scher, Emmanuel S. Antonarakis, and Daniel J. George. “Reply to L. Dirix, B. De Laere et al, and A. Sharp et al..” J Clin Oncol 37, no. 24 (August 20, 2019): 2184–86. https://doi.org/10.1200/JCO.19.01230.

PMID
31265357
Full Text

Armstrong, Andrew J., Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer..” J Clin Oncol, July 22, 2019. https://doi.org/10.1200/JCO.19.00799.

PMID
31329516
Full Text

Zhu, Jason, Matthew Tucker, Daniele Marin, Rajan T. Gupta, Patrick Healy, Michael Humeniuk, Casey Jarvis, et al. “Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer..” Urol Oncol, July 18, 2019. https://doi.org/10.1016/j.urolonc.2019.06.015.

PMID
31327751
Full Text

Tucker, Matthew D., Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, et al. “Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer..” Cancer Med, July 3, 2019. https://doi.org/10.1002/cam4.2375.

PMID
31270961
Full Text

McNamara, Megan Ann, Taofik Oyekunle, Bennett B. Chin, Jorge Oldan, Aseem Anand, Michala Ritz, Lindsey Shantzer, Monika Anand, Andrew J. Armstrong, and Daniel J. George. “Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer..” Prostate 79, no. 10 (July 2019): 1106–16. https://doi.org/10.1002/pros.23822.

PMID
31045266
Full Text

Bueren, Moritz von, Andrew J. Armstrong, Russell Szmulewitz, Daniel Petrylak, Arnauld Villers, Arun Azad, Antonio Alcaraz, et al. “Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES.” In Swiss Medical Weekly, 149:16S-16S. E M H SWISS MEDICAL PUBLISHERS LTD, 2019.

Scholars@Duke

Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma..” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.

PMID
30858035
Full Text

Jolly, Mohit Kumar, Kathryn E. Ware, Shengnan Xu, Shivee Gilja, Samantha Shetler, Yanjun Yang, Xueyang Wang, et al. “E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms..” Mol Cancer Res 17, no. 6 (June 2019): 1391–1402. https://doi.org/10.1158/1541-7786.MCR-18-0763.

PMID
30862685
Full Text

Sonpavde, Guru, Neeraj Agarwal, Gregory Russell Pond, Rebecca J. Nagy, Roberto H. Nussenzveig, Andrew W. Hahn, Oliver Sartor, et al. “Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer..” Cancer 125, no. 9 (May 1, 2019): 1459–69. https://doi.org/10.1002/cncr.31959.

PMID
30620391
Full Text

Armstrong, Andrew J., Susan Halabi, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, et al. “Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study..” J Clin Oncol 37, no. 13 (May 1, 2019): 1120–29. https://doi.org/10.1200/JCO.18.01731.

PMID
30865549
Full Text

Pages